Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids

Arthritis Care and Research

Volumn 71, Issue 9, 2019, Pages 1249-1254

  Curtis, Jeffrey R ^a   Xie, Fenglong ^a   Yang, Shuo ^a   Bernatsky, Sasha ^b   Chen, Lang ^a   Yun, Huifeng ^a   Winthrop, Kevin ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHOTREXATE; TOFACITINIB; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SEX FACTOR; VACCINATION; AGED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; ECONOMICS; FACTUAL DATABASE; FOLLOW UP; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME FACTOR; UNITED STATES;

AGED; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HERPES ZOSTER; HUMANS; INCIDENCE; JANUS KINASE INHIBITORS; MALE; MEDICARE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERIDINES; PYRIMIDINES; PYRROLES; RISK ASSESSMENT; TIME FACTORS; UNITED STATES;

EID: 85071700649     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23769     Document Type: Article

References (12)

1. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617–29.
2. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2675–84.
3. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1843–7.
4. Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Valdez H, Hirose T, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017;69:1960–8.
5. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol 2017;69:1969–77.
6. Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, et al. Studies with herpes zoster vaccines in immune compromised patients. Expert Rev Vaccines 2017;16:1217–30.
7. Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol 2018;187:161–9.
8. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) 2015;67:731–6.
9. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009;301:737–44.
10. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2015;67:1671–8.
11. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20:488–95.
12. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43–9.